

Ref. No: 1653
Date: 03/04/25
Subject: Atopic Dermatitis

REQUEST

I am analysing the treatment of dermatological conditions in the UK so how many patients were treated in the last 4 months (December 2024 to March 2025) by the dermatology department with each of the following products:

- Abrocitinib
- Baricitinib
- Dupilumab
- Lebrikizumab
- Tralokinumab
- Upadacitinib
- Nemolizumab

RESPONSE

Abrocitinib	0
Baricitinib	7
Dupilumab	<5
Lebrikizumab	0
Tralokinumab	0
Upadacitinib	9
Nemolizumab	0

<5

Due to the low number of patients which is less than five for the period, the Trust is withholding the actual number under section 40 – Personal Information of the Freedom of Information Act due to likelihood of identification of the individual(s).

If the requestor or any other member of the general public can, on the balance of probabilities, identify individuals by cross-referencing the anonymised data with other information that was available to them, then the information is personal data and exempt from disclosure under the Act.